Ligand Pharmaceuticals, Inc. - Class B


Market Cap$1.28B

Compare Ligand Pharmaceuticals

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Ligand Pharmaceuticals, Inc. - Class BLigand Pharmaceuticals, Inc. - Class B77.50%2%10.8-
marketMarket Avg49.61.28%30%6.11.1
HealthcareHealthcare Avg32.71.25%19%7.40.9

Current Fair Value

21.6% upside

Undervalued by 21.6% based on the discounted cash flow analysis.

Share Statistics

Market cap$1.28 Billion
Enterprise Value$1.09 Billion
Dividend Yield$0.0 (0.0%)
Earnings per Share$0.95
Outstanding Shares17,355,257
Avg 30 Day Volume108,579


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio77.46
Price to Sales10.84
Price to Book Ratio2.0
Enterprise Value to Revenue8.34
Enterprise Value to EBIT15.21
Enterprise Value to Net Income65
Total Debt to Enterprise0
Debt to Equity0

Revenue Sources

No data

ESG Score

No data

About Ligand Pharmaceuticals, Inc.

CEO: John Higgins